Loading...
Publication
Enamel matrix derivative in the treatment of peri-implant diseases - a systematic review
| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| PPG_34348 | 490.25 KB | Adobe PDF |
Authors
Advisor(s)
Abstract(s)
Objective: To evaluate the benefit in terms of clinical, histological and radiographic
outcomes of the adjunctive use of enamel matrix derivative (Emdogain®
; Straumann,
Basel, Switzerland) on the non-surgical and surgical treatment of peri-implant diseases.
Methods: A systematic literature search comprised three databases: PubMed, Scopus
and Cochrane. Eligible studies were selected based on the inclusion criteria.
Results: Seven studies were selected for data extraction. Two randomized clinical trials
using Emdogain®
as an adjuvant for non-surgical treatment of peri-implant mucositis;
tree cohort studies and and two randomized clinical trials using Emdogain®
as an
adjuvant for surgical treatment of peri-implantitis. A reduction of the mean bleeding on
probing (76.6%), probing depth (3.5mm), P. gingivalis counts and mean marginal bone
level gain of 2,38±0.92mm was observed.
Conclusions: Emdogain® has a positive effect on clinical and microbiological outcome
of non-surgical treatment of peri-implant mucositis. Combined with grafting materials,
it seems to improve bone fill after surgical treatment of peri-implantitis. More studies
are necessary to determine the effects of Emdogain®
alone in the clinical outcome of
peri-implantitis treatment.
Description
Keywords
Peri-implant diseases Non-surgical Surgical Treatment Enamel matrix derivative Emdogain®